Abstract: Certain aspects of the disclosure concern a device for repairing or replacing a native heart valve. The device can include a frame including a first set of struts intersecting with a second set of struts at a plurality of strut connection points. The frame can be radially expandable from a radially collapsed state to a radially expanded state. The device can include at least one expansion feature including a screw head and a screw shaft connected to the screw head. The screw shaft can extend through a first strut connection point and a second strut connection point. The device can further include a plurality of penetrating members extending from a first end of the frame. Rotating the screw shaft in a first direction can radially expand the frame from the radially collapsed state to the radially expanded state.

Abstract: The present inhibitory polypeptides/peptides are derived from an envelope (E) protein of a coronavirus (e.g., human coronaviruses such as SARS-CoV-2). The polypeptides/peptides against coronaviruses can be used to treat or prevent infection by a coronavirus in a subject.

Abstract: The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: The subject matter disclosed herein relates to a recombinant spike (S) protein from the B.1.351.2-7 variant of the SARS-CoV-2 virus, the DNA and RNA nucleotide sequences encoding the recombinant B.1.351.2-7 spike protein, and engineered antibodies that bind the B.1.351.2-7 spike protein and neutralize the B.1.351.2-7 virus.

Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.

Abstract: The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

Abstract: Disclosed herein is a kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, including a first antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and a second antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 13, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 14.

Abstract: The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

Abstract: The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.

Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.